MSB 2.08% 94.0¢ mesoblast limited

Ann: Mesoblast 2023 Full Year Financial Results Webcast, page-32

  1. 904 Posts.
    lightbulb Created with Sketch. 3046
    Thanks Wilba. I hope you're feeling better. I also appreciate your time and effort.

    Yes, so true about the infections, which is the leading cause of death in aGvHD after NRM. Even infections controlled with antibiotics can cause intestinal dysbiosis, which can impact long-term survival.

    The ref. I believe is to the paper by Hill et al. which OP also shared a link to. I take issue with their definition of remission. They say Rux was "highly effective" in SR aGvHD but the link is to Reach2 which trialed Rux against the mother of all toxic crap in 50% of the BAT arm and still only then managed to show mortality benefit for a few more months. The authors state high efficacy in skin and link to a clearly flawed real-world study by Zeiser et al.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
94.0¢
Change
-0.020(2.08%)
Mkt cap ! $1.073B
Open High Low Value Volume
95.5¢ 97.0¢ 93.5¢ $1.424M 1.507M

Buyers (Bids)

No. Vol. Price($)
8 29390 93.5¢
 

Sellers (Offers)

Price($) Vol. No.
94.5¢ 14089 2
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.